A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors

NCT03386942 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: Farletuzumab Ecteribulin

Sponsor

Eisai Inc.